PMID- 35084306
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20221108
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 40
IP  - 11
DP  - 2022 Nov
TI  - CXCL-13 serum levels in patients with rheumatoid arthritis treated with 
      abatacept.
PG  - 2103-2108
LID - 10.55563/clinexprheumatol/sk0rx7 [doi]
AB  - OBJECTIVES: C-X-C motif chemokine 13 (CXCL-13), which is expressed by synovial 
      follicular dendritic cells and activated mature antigen-experienced T-helper 
      cells, has been described as a surrogate marker of lymphoid phenotype of 
      synovitis in rheumatoid arthritis (RA). A preferential response to 
      anti-interleukin-6 receptor (IL-6R) as compared to anti-tumour necrosis factor 
      alpha (TNFalpha) monotherapy has been described in patients with increased levels of 
      CXCL-13. We hypothesised that serum levels of CXCL-13 could be used as a 
      biomarker of response to treatment with abatacept (ABA), a T-cell co-stimulation 
      blocker. METHODS: Serum levels of CXCL-13 and of soluble intracellular adhesion 
      molecule 1 (sICAM-1) (a putative marker of the myeloid subtype of synovitis) were 
      measured by indirect solid-phase enzyme immunoassays, before (T0) and after 6 
      months of therapy with ABA (T6) in 63 patients with RA. Circulating T follicular 
      helper cells and B cell subpopulations were identified by flow-cytometry. 
      RESULTS: At T0, CXCL-13 serum levels were higher in RA patients than in healthy 
      controls (p=0.0001) and correlated with disease activity, while no difference 
      between the two groups was observed as far as sICAM-1 levels. Serum levels of 
      CXCL-13 levels decreased after therapy with ABA both in patients who achieved a 
      clinical response (p<0.01) and in non-responders (p=0.01), whereas sICAM-1 levels 
      did not significantly change. When comparing RA patients who responded to ABA 
      with non-responders no significant difference of baseline serum levels of CXCL-13 
      was observed. CONCLUSIONS: CXCL-13 serum levels are raised in RA patients and 
      decrease after therapy with ABA. We were not able to demonstrate that serum 
      CXCL-13 levels predict the clinical response to ABA in RA patients.
FAU - Masneri, Stefania
AU  - Masneri S
AD  - Rheumatology and Clinical Immunology Unit, Department of Clinical and 
      Experimental Sciences, ASST Spedali Civili and University of Brescia, Italy.
FAU - Piantoni, Silvia
AU  - Piantoni S
AD  - Rheumatology and Clinical Immunology Unit, Department of Clinical and 
      Experimental Sciences, ASST Spedali Civili and University of Brescia, Italy. 
      slv.piantoni@gmail.com.
FAU - Galoppini, Giorgio
AU  - Galoppini G
AD  - Rheumatology and Clinical Immunology Unit, Department of Clinical and 
      Experimental Sciences, ASST Spedali Civili and University of Brescia, Italy.
FAU - Regola, Francesca
AU  - Regola F
AD  - Rheumatology and Clinical Immunology Unit, Department of Clinical and 
      Experimental Sciences, ASST Spedali Civili and University of Brescia, Italy.
FAU - Nalli, Cecilia
AU  - Nalli C
AD  - Rheumatology and Clinical Immunology Unit, Department of Clinical and 
      Experimental Sciences, ASST Spedali Civili and University of Brescia, Italy.
FAU - Bazzani, Chiara
AU  - Bazzani C
AD  - Rheumatology and Clinical Immunology Unit, Department of Clinical and 
      Experimental Sciences, ASST Spedali Civili and University of Brescia, Italy.
FAU - Franceschini, Franco
AU  - Franceschini F
AD  - Rheumatology and Clinical Immunology Unit, Department of Clinical and 
      Experimental Sciences, ASST Spedali Civili and University of Brescia, Italy.
FAU - Airo, Paolo
AU  - Airo P
AD  - Rheumatology and Clinical Immunology Unit, Department of Clinical and 
      Experimental Sciences, ASST Spedali Civili and University of Brescia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220127
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 7D0YB67S97 (Abatacept)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - Abatacept/therapeutic use
MH  - *Arthritis, Rheumatoid/diagnosis/drug therapy
MH  - *Synovitis/pathology
MH  - Biomarkers
MH  - Flow Cytometry
EDAT- 2022/01/28 06:00
MHDA- 2022/11/09 06:00
CRDT- 2022/01/27 12:14
PHST- 2021/07/22 00:00 [received]
PHST- 2021/12/09 00:00 [accepted]
PHST- 2022/01/28 06:00 [pubmed]
PHST- 2022/11/09 06:00 [medline]
PHST- 2022/01/27 12:14 [entrez]
AID - 17712 [pii]
AID - 10.55563/clinexprheumatol/sk0rx7 [doi]
PST - ppublish
SO  - Clin Exp Rheumatol. 2022 Nov;40(11):2103-2108. doi: 
      10.55563/clinexprheumatol/sk0rx7. Epub 2022 Jan 27.